Category: Intellectual property
-
Patent Issued for Peptides in Diabetes Gene Therapy
A U.S. patent was issued today for synthetic peptides that support gene therapies developed to treat type 2 diabetes and heart failure.
-
Patent Office Decides for Broad and Editas in Crispr Case
The U.S. Patent and Trademark Office decided that the gene editing processes developed by Broad Institute and licensed to Editas Medicine do not interfere with techniques for genome editing created by University of California at Berkeley.
-
Tissue Regeneration Start-Up Gains $33M in Early Funds
A new enterprise founded by researchers at Stanford University aims to discover and develop drugs that repair and regenerate tissue from stem cells.
-
Biotechs License Solid Tumor Therapy in $2.1B Deal
Biotechnology enterprise Immunomedics Inc. is licensing its enhanced antibody-based treatment for solid tumor cancers to Seattle Genetics, a developer of similar cancer drugs.
-
Univ. Spin-Off Offering Pediatric Care Software
A company spun-off from Indiana University is marketing software written in its medical school to relate pediatric clinical guidelines to parents’ concerns during office visits.
-
Protein Drug Discovery Company Launches, Gains $50M
A biotechnology enterprise founded by faculty at Scripps Research Institute plans to discover new therapies based on complex interactions with human proteins.
-
Simpler Lab Cell Production Techniques Devised
A process is being developed that makes it easier to produce healthy and diseased cells in the lab from human specimens for regenerative medicine and research.
-
Scripps, Pfizer Collaborate on DNA-Coded Drug Discovery
Drug maker Pfizer Inc. is gaining access to advances in a synthetic chemistry technology developed by Scripps Research Institute that tags compounds with DNA identifiers.
-
Sanofi Licensing Antibody for Autoimmune Diseases
The global drug company Sanofi is licensing a synthetic antibody to treat autoimmune disorders being developed by a spin-off enterprise from Dartmouth College.
-
Ionis Options Cardiac Drugs in $1.5 Billion Deal
Biotechnology company Ionis Pharmaceuticals is providing drug maker Novartis first access to two experimental drugs for controlling proteins that promote cholesterol and triglycerides, which contribute to heart disease.